400 Professional Drive
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
459 articles with Emergent BioSolutions
11/10/2020According to BioSpace research, only 48% of biotech professionals feel there is a career development path for all employees at their current company. Do you have a career development path?
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
Emergent BioSolutions Inc. reported financial results for the three and nine months ended September 30, 2020 and updated its full year 2020 guidance.
Emergent BioSolutions to Release Third Quarter 2020 Financial Results and Conduct Conference Call on November 5, 2020
Emergent BioSolutions Inc. will host a conference call on Thursday, November 5, 2020 at 5:00 pm to discuss the financial results for the third quarter of 2020, recent business developments, revenue guidance for the fourth quarter of 2020, and financial outlook for full year 2020.
10/12/2020It was a moderately busy week for clinical trial news. Here’s a look.
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19
NIAID has initiated a Phase 3 clinical trial to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19 Emergent is planning additional clinical trials to evaluate COVID-HIG for potential use in other patient populations or individuals at high risk of exposure GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolution
Emergent BioSolutions Teams Up with Boston Red Sox, Cincinnati Reds, Philadelphia Phillies, and MAPDA to Highlight Importance of Overdose Reversal Medicines on International Overdose Awareness Day
Organizations Join Together to Raise Awareness of Overdose Reversal Medicines During August 31st Games
Emergent BioSolutions Inc. announced that the company’s board of directors appointed Marvin L. White as a Class II director to serve on the board effective October 1, 2020, with an initial term expiring at the 2023 annual meeting of stockholders.
Emergent BioSolutions Inc. announced that members of the company’s executive management team will participate in the following virtual investor conferences through the end of September 2020
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration has approved the extension of the shelf life of NARCAN® Nasal Spray from 24 months to 36 months.
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450 million in aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Notes”). The Notes are fully and unconditionally guaranteed on a senior unsecured basis by all of the Company’s direct and indirect subsidiaries that guarantee debt under its credit facilities. The Company has used the
Emergent BioSolutions Announces Upsize and Pricing of $450 Million of 3.875% Senior Unsecured Notes Due 2028
Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the “Notes”), representing an increase of $50 million in aggregate principal amount from the initially proposed offering size.
Emergent BioSolutions Inc. announced that it intends to offer $400 million aggregate principal amount of senior unsecured notes with an expected maturity date of August 2028.
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2020 and Revises Upward Full Year 2020 Guidance
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the three and six months ended June 30, 2020 and revised upward full year 2020 guidance.
Gaithersburg, Maryland-based Emergent BioSolutions inked another manufacturing agreement to support the development of a vaccine against COVID-19, the disease caused by the novel coronavirus.
Emergent BioSolutions Signs Agreement with AstraZeneca to Expand Manufacturing for COVID-19 Vaccine Candidate
Emergent BioSolutions Inc. announced that it has signed an agreement to provide contract development and manufacturing services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
Emergent BioSolutions Inc. (NYSE: EBS) today announced that Standard & Poor’s (S&P) has indicated that the company will be added to the S&P MidCap 400® index, effective prior to the open of trading on Friday, July 24.
Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020
Emergent BioSolutions Inc. will host a conference call on Thursday, July 30, 2020 at 5:00 pm to discuss the financial results for the second quarter of 2020, recent business developments, revenue guidance for the third quarter of 2020, and financial outlook for full year 2020.
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
Emergent BioSolutions Inc. announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology.
Emergent will handle contract development and manufacturing (CDMO) services in a deal that is valued at about $480 million for the first two years.